Prevention & lipidsCohort study
Association of Lipoprotein(a) and Interleukin-6 With Cardiovascular Risk
- Prospective cohort study
- 2 independent primary prevention cohorts (MESA, UK Biobank)
Authors' conclusion
In 2 independent primary prevention cohorts, Lp(a) and IL-6 were independent predictors of ASCVD risk, and their combination identified individuals at highest risk.
Study context
- Population
- Primary prevention cohorts (MESA and UK Biobank)
- Participants
- 6,514 vs 26,574
- Exposure
- Lp and IL-6, separately and combined, and CV risk
- MESAn = 6,514
- UK Biobank (UKB)n = 26,574
- Outcome
- CHD (MI or resuscitated cardiac arrest), per SD of Lp(a) and IL-6
Main finding
As reported in the abstract
CHD events, evaluated separately (HR per SD)
Hazard ratio (95% CI)
Lp(a)MESA
1.13(1.04–1.23)
Lp(a)UKB
1.11(1.09–1.13)
IL-6MESA
1.22(1.10–1.35)
IL-6UKB
1.19(1.15–1.24)
Per SD, as printed
Observational data: associations, not effects.
Further findings
Coronary heart disease (CHD), high Lp(a) (>50 mg/dL) and high IL-6 (> median)
| Comparison | HR (95% CI) | |
|---|---|---|
| Both high · MESA | 1.72 (1.25–2.36) | |
| Both high · UKB | 1.39 (1.12–1.72) | |
| 0.512Hazard ratio (log scale) |
ASCVD and peripheral vascular disease (PVD)
- Similar results as for CHD
CHD, high Lp(a) (>50 mg/dL) and high IL-6 (> median)
- Strongest association for each outcome when both levels high
Original publication
Association of Lipoprotein(a) and Interleukin-6 With Cardiovascular Risk. J Am Coll Cardiol. Published 10 November 2025. doi:10.1016/j.jacc.2025.08.101
Summarised from the published abstract; every number is checked against it